(Q34563071)

English

Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1 reference

Europe PubMed Central

Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

2

object named as

Greg L Plosker

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1

object named as

Kate McKeage

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

publication date

1 January 2002

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

62

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

633-653

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

https://scigraph.springernature.com/pub.10.2165/00003495-200262040-00009

0 references

Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alfuzosin, a selective alpha 1-adrenoceptor antagonist in the lower urinary tract

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Benign prostatic hyperplasia. Practical treatment guidelines

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Medical therapy for benign prostatic hyperplasia: a review of the literature

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. DUALF Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Medical therapy for benign prostatic hyperplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Future concepts in the medical therapy of benign prostatic hyperplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacotherapy for benign prostatic hyperplasia--the potential for alpha 1-adrenoceptor subtype-specific blockade

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alpha-adrenoceptors and muscarinic receptors in the isolated human prostate.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subtype selective alpha1-adrenoceptor antagonists for the treatment of benign prostatic hyperplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Haemodynamic and pharmacokinetic evaluation of alfuzosin in man. A dose ranging study and comparison with prazosin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationship between the effects of alfuzosin on rat urethral and blood pressures and its tissue concentrations

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alpha blockers: are all created equal?

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term quality of life in patients with benign prostatic hypertrophy: preliminary results of a cohort survey of 7,093 patients treated with an alpha-1-adrenergic blocker, alfuzosin. QOL BPH Study Group in General Practice.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Placebo effects in the pharmacological treatment of uncomplicated benign prostatic hyperplasia. The ALFECH Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11893233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-200262040-00009

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34563071&oldid=1555501021"